top of page

ATS2024: Gossamer Bio presented open label extension data for seralutinib, an inhibitor of PDGFR, CSF1R, and c-KIT, in PAH showing durability of effect at 72 weeks

CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but improving at 72 weeks vs 24 weeks. Mr. Hasnian also recaps a transformative partnership with Chiesi that was announced earlier this month.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page